United Therapeutics Corporation (UTHR) Shareholders & Insider Trades
United Therapeutics shareholders at a glance
The largest holder of United Therapeutics stock is BlackRock Advisors LLC, with 4.6 million shares (10.90% of the company), worth about $2.36 billion as of September 25, 2026. The 10 largest holders together own 44.2%.
In Q2 2026, 911 institutional holdings reports listed shares worth $22.70 billion.
Insiders reported 101 transactions in the last two years: 50 sales worth $262.80 million and no purchases. The newest one on file is from May 14, 2026 (Rothblatt Martine A, Chief Executive Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 14, 2026.
United Therapeutics Corporation
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest United Therapeutics shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 4.6 million | 10.90% | $2.4B |
| Avoro Capital Advisor LLC | 2.8 million | 6.54% | $1.4B |
| Vanguard Portfolio Management LLC | 1.9 million | 4.52% | $980.0M |
| Vanguard Capital Management LLC | 1.9 million | 4.52% | $979.0M |
| State Street Corporation | 1.9 million | 4.47% | $969.0M |
| Renaissance Technologies LLC | 1.7 million | 4.03% | $872.0M |
| Wellington Trust Co., NA | 1.4 million | 3.25% | $704.0M |
| Geode Capital Management LLC | 996,598 | 2.35% | $509.0M |
| Janus Henderson Investors US LLC | 831,129 | 1.96% | $424.0M |
| Norges Bank (13F) | 694,753 | 1.64% | $355.0M |
As of September 25, 2026.
United Therapeutics institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 911 | – | $22.7B |
| Q1 2026 | 901 | 41.5 million | $24.6B |
| Q4 2025 | 868 | 42.2 million | $20.5B |
| Q3 2025 | 761 | 41.2 million | $17.3B |
| Q2 2025 | 702 | 44.1 million | $12.7B |
| Q1 2025 | 699 | 45.0 million | $13.9B |
| Q4 2024 | 706 | 44.3 million | $15.6B |
| Q3 2024 | 656 | 44.2 million | $15.8B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
United Therapeutics insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Rothblatt Martine A | May 14, 2026 | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.03 per share. | $1.4M |
| Edgemond James | May 14, 2026 | Chief Financial Officer | Conversion of Exercise of derivative security at price 135.42 per share. | $1.4M |
| Rothblatt Martine A | May 14, 2026 | Chief Executive Officer | Sale at price 568.69 - 578.29 per share. | $5.5M |
| Edgemond James | May 14, 2026 | Chief Financial Officer | Sale at price 568.74 - 578.58 per share. | $5.7M |
| Rothblatt Martine A | May 13, 2026 | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.03 per share. | $1.4M |
| Rothblatt Martine A | May 13, 2026 | Chief Executive Officer | Sale at price 575.40 - 583.81 per share. | $5.5M |
| Rothblatt Martine A | May 12, 2026 | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.03 per share. | $1.4M |
| Rothblatt Martine A | May 12, 2026 | Chief Executive Officer | Sale at price 568.83 - 583.44 per share. | $5.5M |
| Mesa Nilda | May 12, 2026 | Director | Sale at price 581.94 per share. | $150,139 |
| Rothblatt Martine A | May 11, 2026 | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.03 per share. | $1.4M |
| Edgemond James | May 11, 2026 | Chief Financial Officer | Conversion of Exercise of derivative security at price 135.42 per share. | $1.4M |
| Rothblatt Martine A | May 11, 2026 | Chief Executive Officer | Sale at price 569.50 - 580.44 per share. | $5.4M |
Newest 12 of 101 insider transactions in the last two years.
Questions and answers
Who owns the most United Therapeutics stock?
BlackRock Advisors LLC, with 10.90% of the company (as of September 25, 2026). Next: Avoro Capital Advisor LLC (6.54%) and Vanguard Portfolio Management LLC (4.52%).
How many institutions own United Therapeutics stock?
911 institutional holdings reports listed United Therapeutics shares in Q2 2026 worth $22.70 billion.
Are United Therapeutics insiders buying or selling the stock?
In the last two years insiders reported 50 sales and no purchases (101 transactions in all); the newest on file is from May 14, 2026.
